all report title image
  • Published On : May 2017
  • Code : CMI368
  • Industry : Pharmaceutical
  • Pages : 75
  • Formats :

Contraceptive Drugs and Devices – Choice to Conceive, Not Concede

As per stats released by Guttmacher Institute, there were around 61 million women in the U.S. in the childbearing age group (15-44 years) in 2014. Around 10% of these women do not use any contraceptive method. The UN estimates (2015) that unmet need for contraceptives in the North America region is 7%. Thus, there still is an untapped market in the U.S. that contraceptive manufacturers can address. Furthermore, with no-cost coverage insurance policy for sterilization, growth for U.S. contraceptive drugs and devices market is restricted.

Statistics revealed by the United Nations in 2015, mentions that sterilization is a dominant contraceptive method in regions such as North America. Intra-uterine devices (IUDs), vaginal rings, injectables, implants, combined oral contraceptives, and patches are some of the advanced contraceptive methods available in the market. Therefore, various strategies such as promotion through sales force, social media promotion, awareness campaigns, and sampling are adopted by companies marketing contraceptive drugs and devices in the U.S. Introduction of new male contraceptive products with high success rate are projected to shape the course of growth of the U.S. contraceptive drugs and devices market in the near future.

The global U.S. contraceptive drugs and devices market was valued at US$ 6,785.9 million in 2016 and is expected to expand at a CAGR of 5.6% during the forecast period (2016 – 2024)

Figure 1. U.S. Contraceptive Drugs and Devices Market, Major Brand Patent Expirations

Drug/Device Type Brand Patent Expiry Year
Pill Seasonale 2017
Femcon-FE 2019
24 FE
Yaz 2021
Yasmin 2020
IUD Skyla & Kyleena 2023
Vaginla Ring Nuva-Ring 2018
         Source: Coherent Market Insights Analysis (2016)

Oral pills resulting in volatility in the U.S. contraceptive drugs and devices market

Private companies have high interest in selling contraceptive pills as they generate continuous revenues for them compared to one-time long acting contraceptive methods. Furthermore, patent expiration is projected to lead to a barrage of generics entering into the market, further reducing overall average cost of drugs and in turn market revenue. Global generic pharmaceutical companies such as Teva Pharmaceuticals, Lupin Laboratories and Cipla Limited are at pace to launch their generic versions. Emergency contraceptive pills are among the most popular category of pills owing to extensive promotion activities to market these products.

Favorable reimbursement scenario increasing adoption of contraceptives among low and middle-income population

Long-acting reversible contraceptives (LARC) are given complete insurance coverage by the U.S. Affordable Care Act. However, oral pills that generate sustainable revenue are of interest to market players. The availability of products and its cost in different sections of the society are affected due to public-private interest disparity.

Furthermore, the State announced insurance coverage of health and reproductive products to continue without any co-pays, co-insurance or deductibles. In addition to this, the new policy would also cover all medically essential abortion services for the U.S. population. This is a much anticipated relief for the general population in the U.S., where around 45% of all pregnancies reported are unintended (CDC, 2009-2013 study data).

Insurance coverage for devices also varies from state to state in the U.S. Few states have low Medicaid reimbursement rates than the cost of the device, while few states provide reimbursement only to those women who have been prescribed such devices. For instance, in California, dispensing of injectable contraceptives is only allowed by clinics, while Alabama, Idaho, and South California do not cover emergency contraceptive pills as part of the Medicaid programs in their respective states. Many such limitations in Medicaid coverage creates disparity in demand for certain contraceptives across regions in the U.S. Efforts to standardize the rule all over the country is expected to benefit the population at large and the overall U.S. contraceptive drugs and devices market.

Preference for modern contraceptive methods

Higher success rate and availability of reimbursement is encouraging women to opt for these methods over contraceptive pills. With increasing consumer awareness and rising accessibility to modern contraceptives methods, demand for these products is expected to increase during the forecast period. As per the United Nation’s 2015 report, 9 out of 10 married or in-union women opt for modern contraceptive methods. Furthermore, gynecologists and sexologists are recommending use of long-acting reversible contraceptives for couples who do not intend to have a child in near future, owing to their high affectivity compared to conventional contraceptives such as oral hormonal pills.

Contraceptives are birth spacing products that aid in avoiding unplanned pregnancy. There are five widely used contraceptive methods, namely sterilization, hormonal method, barrier method, emergency contraception, and intrauterine method. Sterilization is the most common method implemented globally. While there are a plethora of female contraceptives available in the market, companies and a few University researchers are trying to introduce male contraceptive methods. Women contraceptive methods include vaginal rings, diaphragms, female condoms, oral pills, and intra-uterine devices (IUD). Selecting the most appropriate method is critical to avoid undesired side effects. The use of contraceptives can avoid 60% of maternal deaths and 57% of child deaths worldwide, as opined by the World Health Organization (WHO) in 2014. Therefore, various family planning initiatives have been introduced by governmental and non-governmental agencies in order to create awareness about prevention of unplanned pregnancy.

Market Dynamics

Companies present in the contraceptives market prefer marketing oral contraceptive pills to churn out considerable and constant revenues compared to one-time revenue generated through long-acting contraceptives. Moreover, there is heavy promotion of oral pills compared to the long acting contraceptives such as IUD, and implant. This has kept the consumers away from the real benefits of long acting contraceptives over the oral pills. This is the reason that oral pills dominate the U.S. contraceptive drugs and devices market. The oral pills market is projected to experience the entry of generics with patent expirations nearing in the forecast period.

However, demand for advanced contraceptive options such as IUD, injectables, implants and diaphragms is observed to be high globally. This is owing to growing awareness among the populace, availability of reimbursement and growing demand for long term contraceptive methods. Government promotes the use of IUD and implants i.e. long-acting contraceptives for better therapeutic effect and safety. Also, reimbursement schemes are made attractive for consumers to opt for these contraceptive methods.

Market Taxonomy

This report segments the U.S. contraceptives drugs and devices market on the basis of product type and geography. On the basis of product type, the U.S. contraceptives drugs and devices market is segmented into drug and devices. Drugs are further sub-segmented into oral pills, injectables, and topical contraceptives. The contraceptive devices segment is further sub-segmented into male contraceptives devices and female contraceptives devices. Female contraceptives devices include female condoms, contraceptive diaphragms, contraceptive sponges, and contraceptive vaginal rings. Intrauterine devices, and subdermal contraceptive implants.

Key features of the study:

  • This report provides in-depth analysis of the U.S. contraceptives drugs and devices and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR (%)) for the forecast period: 2016 – 2024, considering 2015 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches, approvals, regional outlook, and competitive strategies adopted by the leading players
  • It profiles leading players in the U.S. contraceptives drugs and devices market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies and future plans
  • Key companies covered as a part of this study include Teva Pharmaceutical Industries Ltd., Church & Dwight Co. Inc., Reckitt Benckiser Plc, Pfizer, Inc., Bayer AG, Mayer Laboratories, Inc., The Female Health Company, Cooper Surgical, Inc., Allergan plc, Cipla Limited, and Merck & Co. Inc.
  • Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launches, market expansion, and marketing tactics
  • The U.S. contraceptives drugs and devices market report caters to various stakeholders in this industry, including investors, drug and device manufacturers, distributors and suppliers for contraceptives drugs and devices, government organizations, research and consulting firms, new entrants, and financial analysts
  • Various strategy matrices used in analyzing the contraceptives drugs and devices market would provide stakeholders vital inputs to make strategic decisions accordingly

Detailed Segmentation:

  • U.S. Contraceptives Drugs And Devices Market, By Product Type:
    • Contraceptive Drugs
      • Oral Contraceptive Pills
      • Contraceptive Injectables
      • Topical Contraceptives
    • Contraceptive Devices
      • Male Contraceptive Devices
        • Condoms
      • Female Contraceptive Devices
        • Female Condoms
        • Contraceptive Diaphragms
        • Contraceptive Sponges
        • Contraceptive Vaginal Rings
        • Intrauterine Devices
          • Hormonal
          • Copper-T
        • Subdermal Contraceptive Implants
  • Company Profiles
    • Teva Pharmaceutical Industries Ltd.*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Strategies
      • Recent Developments
      • Future Plans
    • Church & Dwight Co. Inc.
    • Reckitt Benckiser Plc
    • Pfizer, Inc.
    • Bayer AG
    • Mayer Laboratories, Inc.
    • The Female Health Company
    • Cooper Surgical, Inc.
    • Allergan Plc
    • Cipla Limited
    • Merck & Co. Inc.

“*” marked represents similar segmentation in other categories in the respective section.

Frequently Asked Questions

The U.S. contraceptives drugs and devices market is estimated to exhibit a CAGR of 5.6% over the forecast period
No-cost coverage insurance policy for sterilization is one of the major factors that is expected to hamper growth of the market over the forecast period
Development and launches of new generic products driven by the expiry of patents is one of the major factors that is expected to propel growth of the market over the forecast period
Introduction of new male contraceptive products and rising preference for modern contraceptive methods are some of the market trends that has been observed in the market

Related Reports


Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo